Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.505 SEK | -3.58% | -2.64% | +13.43% |
May. 21 | OncoZenge AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 41.05M 435M |
---|---|---|---|---|---|
Net income 2024 * | -8M -84.85M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 3M 31.82M | Net cash position 2025 * | 3M 31.82M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.15
x | P/E ratio 2025 * |
-
| Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 33.97% |
1 day | -3.58% | ||
1 week | -5.40% | ||
Current month | -5.78% | ||
1 month | -10.01% | ||
3 months | -15.64% | ||
6 months | +0.14% | ||
Current year | +13.43% |
Managers | Title | Age | Since |
---|---|---|---|
Stian Kildal
CEO | Chief Executive Officer | - | 23-09-12 |
Michael Owens
DFI | Director of Finance/CFO | 68 | 23-10-11 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christoph Nowak
BRD | Director/Board Member | 38 | 23-09-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 3.505 | -3.58% | 18,610 |
24-05-24 | 3.635 | +4.15% | 30,856 |
24-05-23 | 3.49 | -2.92% | 47,153 |
24-05-22 | 3.595 | -0.14% | 6,313 |
24-05-21 | 3.6 | 0.00% | 21,433 |
Delayed Quote Nasdaq Stockholm, May 27, 2024 at 09:13 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+13.43% | 4M | |
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- ONCOZ Stock